Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
AssigneeLyvgen Biopharma Holdings Limited
InventorJieyi WANG
Life of this patent
Estimating the term…
Abstract
Human IgG1, IgG2, and IgG4 mutants having mutations in the hinge domain and exhibiting altered binding activity to Fcγ receptors such as FcγRIIB (CD32B). Also provided herein are methods for selectively activating immune responses in a subject using a therapeutic agent capable of targeting both an immune cell surface receptor and FcγRIIB.
Claims48
A protein comprising a variant Fc region, wherein the variant Fc region comprises a mutation at any of positions 218-329 as compared to a wild-type parent Fc region, and wherein the numbering is according to the EU index.
A protein comprising a variant Fc region of an IgG2 or IgG4 molecule, wherein the variant Fc region comprises a mutation at position 267, position 273, position 328, or a combination thereof as compared to a wild-type parent IgG2 or IgG4 Fc region, and wherein the numbering is according to the EU index.
A method for selectively activate an immune response in a subject, the method comprising administering to a subject in need thereof an effective amount of a therapeutic agent, wherein the therapeutic agent comprises a first moiety that binds an immune cell receptor and a second moiety that binds FcγRIIB.
Dependencies are inferred from the claim text.